@jamaoncology.com - JAMA Oncology

05 Nov 2026 17:00 +0000

Among trainees providing #CancerCare, representation of physicians from groups underrepresented in medicine increased after 2020, but still did not match the diversity of the general US population in 2025. ja.ma/4zxXSEq

15 Oct 2026 15:30 +0000

For localized deficient mismatch repair or microsatellite instability–high #GastricCancer and gastroesophageal junction adenocarcinoma, neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival. ja.ma/4ex2nGw

10 Oct 2026 16:00 +0000

💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring. ja.ma/4hVydhi

10 Oct 2026 14:00 +0000

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/4j8TEO5

08 Oct 2026 15:30 +0000

Among patients with transurethrally unresectable, ERBB2-positive #BladderCancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. ja.ma/479i4jj

01 Oct 2026 15:30 +0000

Among patients with #HepatocellularCarcinoma beyond the Milan criteria who underwent #LiverTransplant, an immune checkpoint inhibitor–based pretransplant strategy was associated with better survival and lower recurrence vs therapy without immune checkpoint inhibitors. ja.ma/4hFlgbb

25 Sep 2026 20:23 +0000

Among patients with nonmetastatic #HeadNeckCancer receiving radiation therapy, financial toxicity was associated with worse quality of life and substantial out-of-pocket expenses. ja.ma/4dzMI8Z

25 Sep 2026 20:22 +0000

This review examines ovarian metastases from colorectral cancer and the potential role of surgical resection of metastatic disease. ja.ma/4iKDA4S

25 Sep 2026 20:20 +0000

Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #Cancer incidence gap in China but only a smaller fraction in the UK. ja.ma/4ygALxm

18 Sep 2026 14:00 +0000

Prebiopsy #MRI use before #ProstateCancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. ja.ma/4gPW16U

18 Sep 2026 13:00 +0000

Editorial: In HPV 16–positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. ja.ma/4xW1IWP

17 Sep 2026 16:00 +0000

Meta-analysis: In #HeadAndNeckCancer with programmed cell death 1 ligand 1 combined positive score <1, #ImmuneCheckpointInhibitors were likely associated with reduced survival, including significantly reduced overall survival in recurrent or metastatic disease. ja.ma/46uMnAC

17 Sep 2026 15:30 +0000

In #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. ja.ma/4xVtvql

10 Sep 2026 15:30 +0000

In persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. ja.ma/3UHjheC

08 Sep 2026 14:00 +0000

A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis? ja.ma/4cvl6kY https://ja.ma/4cvl6kY

08 Sep 2026 13:00 +0000

Among children with relapsed or refractory #BCellAcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. ja.ma/4hc7VYK https://ja.ma/4hc7VYK

07 Sep 2026 16:00 +0000

Among patients with #ERBB2-positive #BreastCancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects. ja.ma/46FBax8

07 Sep 2026 15:00 +0000

💬 Editorial: In pediatric #AcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required. ja.ma/464VxDP https://ja.ma/464VxDP

07 Sep 2026 14:00 +0000

📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3SPjlZi https://ja.ma/3SPjlZi

07 Sep 2026 13:00 +0000

📑 This JAMA Oncology review discusses #Chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #BreastCancer. ja.ma/4x96mzy https://ja.ma/4x96mzy

06 Sep 2026 16:00 +0000

In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4ig46mA

06 Sep 2026 15:00 +0000

#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/4ymxIDm

06 Sep 2026 14:32 +0000

In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/3TbzUyG

06 Sep 2026 14:07 +0000

In Denmark, #Meningioma incidence increased from 2010 to 2023, but #Surgery and #Radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. ja.ma/465TUFZ

06 Sep 2026 14:00 +0000

14 Aug 2026 14:00 +0000

A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4wVRi9f

13 Aug 2026 16:00 +0000

Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/3S5A0Hu